Startseite The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation

  • Janka Franeková , Lenka Hošková , Peter Sečník , Michal Pazderník , Markéta Kotrbatá , Zdeněk Kubíček und Antonín Jabor EMAIL logo
Veröffentlicht/Copyright: 30. Juli 2015
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Changes of biomarkers measured soon after heart transplantation (HTx) can reflect different processes: cardiomyocyte necrosis (troponins, high-sensitivity cardiac TnT and TnI), heart function (natriuretic peptides, BNP and NT-proBNP), fibrosis (galectin-3 and ST2), and global cardiorenal risk (cystatin C). We assessed the prognostic role of hsTnT, NT-proBNP, galectin-3 and cystatin C during the early post-transplant period.

Methods: A total of 121 consecutive post-HTx patients were assessed. The main outcomes were survival, left ventricular ejection fraction (LVEF) and rejection periods. Survival was assessed after intermediate (12 months) and long periods (total follow-up during study, median of survival 763 days, IR 527–1038 days). LVEF was assessed 12 months after HTx. Rejection was evaluated during follow-up. We report biomarker concentrations measured 10 days and 12 months after HTx.

Results: Ten days after HTx, cystatin C and hsTnT predicted death both under univariable and multivariable analysis. These two biomarkers along with galectin-3 were increased in patients with decreased LVEF measured 1 year after HTx. NT-proBNP did not show early prognostic power. None of the measured biomarkers predicted rejection, but hsTnT and NT-proBNP were increased significantly 12 months after HTx in patients with at least one rejection.

Conclusions: Cystatin C and hsTnT measured 10 days after HTx can provide prognostic information on survival and galectin-3 measured at the same time may display a relationship to heart function assessed 1 year after HTx. Further study should be carried out in a large cohort of patients.


Corresponding author: Antonín Jabor, Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Prague, Czech Republic, Phone: +420 236 055236, Fax: +420 261 363023, E-mail: ; and Charles University, 3rd Medical Faculty, Prague, Czech Republic

Acknowledgments

We express our thanks to Dr. V. Lánská for valuable comments on the statistical evaluation of results.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Antonín Jabor received lecturer’s honoraria Abbott Laboratories Ltd., Czech Republic and Roche Ltd., Czech Republic. None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose. The study was partially supported by the project for conceptual development of research organizations 00023001 (Ministry of Health, Czech Republic) and the International Grant Agency of the Ministry of Health of the Czech Republic No NT/11269-5.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7:1–8.10.1007/s11897-010-0004-xSuche in Google Scholar PubMed PubMed Central

2. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15:1095–101.10.1093/eurjhf/hft077Suche in Google Scholar PubMed

3. de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, et al. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther 2014;28:237–46.10.1007/s10557-014-6520-2Suche in Google Scholar PubMed

4. Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013;112:831–7.10.1016/j.amjcard.2013.05.013Suche in Google Scholar PubMed

5. Lok DJ, van Der Meer P, Bruggink-André de la Porte PW, Lipsic E, van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323–8.10.1007/s00392-010-0125-ySuche in Google Scholar PubMed PubMed Central

6. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013;6:219–26.10.1161/CIRCHEARTFAILURE.112.000129Suche in Google Scholar PubMed

7. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932–43.10.1373/clinchem.2009.128397Suche in Google Scholar PubMed

8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327.10.1161/CIR.0b013e31829e8776Suche in Google Scholar PubMed

9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–69.Suche in Google Scholar

10. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054.10.1093/eurheartj/ehr236Suche in Google Scholar PubMed

11. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710–20.10.1016/j.healun.2005.03.019Suche in Google Scholar PubMed

12. Gaze DC, Prante C, Dreier J, Knabbe C, Collet C, Launay JM, et al. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014;52:919–26.10.1515/cclm-2013-0942Suche in Google Scholar

13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD). Kidney Int Suppl 2013;3:1–150.Suche in Google Scholar

14. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Available from: http://www.R-project.org/. Accessed 14 May, 2015.Suche in Google Scholar

15. Harrell FE Jr. RMS: regression modeling strategies. R package version 4.3-1. Available from: http://CRAN.R-project.org/package=rms. Accessed 14 May, 2015.Suche in Google Scholar

16. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J 2003;24:881–2.10.1016/S0195-668X(02)00799-6Suche in Google Scholar

17. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87.10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4Suche in Google Scholar

18. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013;15:1–14.10.1007/s11886-013-0372-4Suche in Google Scholar

19. Woitas RP, Kleber ME, Meinitzer A, Grammer TB, Silbernagel G, Pilz S, et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 2013;229:541–8.10.1016/j.atherosclerosis.2013.04.027Suche in Google Scholar

20. Franeková J, Kubíček Z, Hošková L, Kotrbatá M, Sečník P Jr., Kautzner J, et al. Long-term biological variability of galectin-3 after heart transplantation. Clin Chem Lab Med 2015;53:119–23.10.1515/cclm-2013-1088Suche in Google Scholar

21. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58:267–73.10.1373/clinchem.2011.174359Suche in Google Scholar

22. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60–8.10.3109/07853890.2010.538080Suche in Google Scholar

23. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385–90.10.1016/j.amjcard.2011.03.056Suche in Google Scholar

24. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 2014;167:853–60.e4.10.1016/j.ahj.2014.02.011Suche in Google Scholar

25. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2014;2:260–8.10.1016/j.jchf.2013.12.004Suche in Google Scholar PubMed PubMed Central

26. Beiras-Fernandez A, Weis F, Rothkopf J, Kaczmarek I, Ledderose C, Dick A, et al. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant 2013;18:643–50.10.12659/AOT.889396Suche in Google Scholar PubMed

Received: 2014-12-8
Accepted: 2015-6-18
Published Online: 2015-7-30
Published in Print: 2016-2-1

©2016 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Total error vs. measurement uncertainty: the match continues
  4. Review
  5. Application of fatty acid and lipid measurements in neuropsychiatry
  6. Mini Review
  7. The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity
  8. Opinion Papers
  9. How to report results of prothrombin and activated partial thromboplastin times
  10. Useful measures and models for analytical quality management in medical laboratories
  11. Total error vs. measurement uncertainty: revolution or evolution?
  12. Genetics and Molecular Diagnostics
  13. Rapid detection of Mmalton α1-antitrypsin deficiency allele by real-time PCR and melting curves in whole blood, serum and dried blood spot samples
  14. General Clinical Chemistry and Laboratory Medicine
  15. Diagnostic and clinical significance of Crohn’s disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
  16. Immunoassays for the detection of IgA antibodies to tissue transglutaminase: significance of multiples of the upper limit of normal and inter-assay correlations
  17. Effects of biobanking conditions on six antibiotic substances in human serum assessed by a novel evaluation protocol
  18. Haematology and Coagulation
  19. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study
  20. Reference Values and Biological Variations
  21. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity
  22. Reference intervals for bone turnover markers in Spanish premenopausal women
  23. Cancer Diagnostics
  24. Citrulline as a biomarker of gastrointestinal toxicity in patients with rectal carcinoma treated with chemoradiation
  25. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients
  26. Cardiovascular Diseases
  27. TBX20 loss-of-function mutation associated with familial dilated cardiomyopathy
  28. Cardiac troponin I release after a basketball match in elite, amateur and junior players
  29. The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation
  30. Infectious Diseases
  31. Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis
  32. A comparison of three commercial platforms for urinary NGAL in critically ill adults
  33. Diabetes
  34. Liquid citrate acidification introduces significant glucose bias and leads to misclassification of patients with diabetes
  35. Letter to the Editors
  36. A rare and unstable hemoglobin variant, Hb M Dothan β 25/26 (-GTG), detected by the anomalous cytogram on Sysmex XE-2100
  37. Hb Hope [β136Gly→Asp] and Hb Grady [α119_120insGluPheThr] compound heterozygosity in a Mauritanian patient
  38. Falsely elevated ferritin in patients with a high concentration of rheumatoid factor
  39. Susceptibility of commonly used ferritin assays to the classic hook effect
  40. Comparison of the Elecsys calcitonin assay with the Immulite 1000 assay. Describing one case with heterophilic antibody interference
  41. Performance evaluation of low platelet count and platelet clumps detection on Mindray BC-6800 hematology analyzer
  42. Fetal sex discordance between sequencing-based and real-time PCR non-invasive prenatal test due to a vanishing twin
  43. Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0
  44. A replacement for the testosterone “sex gap”
  45. Added value of indirect immunofluorescence intensity of automated antinuclear antibody testing in a secondary hospital setting
Heruntergeladen am 14.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-1218/html
Button zum nach oben scrollen